SCHEMBL670169

SCHEMBL670169

O=C(NCCO)C1CCNCC1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GNAI3 P08754 1/20 0.60
GNAO1 P09471 1/20 0.60
GNAI1 P63096 1/20 0.60
POLB P06746 1/20 0.47
ALDH1A1 P00352 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
GABRP O00591 1/20 0.45
GABRD O14764 1/20 0.45
GABRA1 P14867 1/20 0.45
TSHR P16473 1/20 0.45
GABRB1 P18505 1/20 0.45
GABRG2 P18507 1/20 0.45
GABRB3 P28472 1/20 0.45
GABRA5 P31644 1/20 0.45
GABRA3 P34903 1/20 0.45
GABRA2 P47869 1/20 0.45
GABRB2 P47870 1/20 0.45
GABRA4 P48169 1/20 0.45
GABRE P78334 1/20 0.45
PMP22 Q01453 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL28808281 0.98 GNAI3 (0.63) GNAI3GNAO1GNAI1POLBALDH1A1
SCHEMBL16364960 0.89 GNAI3 (0.49) GNAI3GNAO1GNAI1POLBALDH1A1
SCHEMBL6135546 0.87 GNAI3 (0.69) GNAI3GNAO1GNAI1POLBALDH1A1
SCHEMBL3987516 0.85
SCHEMBL16908227 0.82 GNAI3 (0.58) GNAI3GNAO1GNAI1POLBALDH1A1
SCHEMBL22124441 0.82 GNAI3 (0.58) GNAI3GNAO1GNAI1POLBALDH1A1
SCHEMBL2262712 0.82 GNAI3 (0.58) GNAI3GNAO1GNAI1POLBALDH1A1
SCHEMBL1438745 0.82 GNAI3 (0.73) GNAI3GNAO1GNAI1POLBALDH1A1
SCHEMBL19301621 0.81 NAAA (0.52) ALDH1A1SMN1; SMN2LMNANAAAKMT2A
SCHEMBL15739433 0.81 NAAA (0.56) ALDH1A1SMN1; SMN2LMNANAAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115819328-A Memantine urea derivative, preparation method thereof and application thereof in preparing medicine for treating soluble epoxide hydrolase mediated diseases 沈阳药科大学 2023-03-21 CN claimed
US-20200109167-A1 SMALL MOLECULE DCN1 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME UNIV MICHIGAN REGENTS (US) 2020-04-09 US claimed
EP-3601245-A1 SMALL MOLECULE DCN1 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME The Regents of The University of Michigan (US) 2020-02-05 EP claimed
WO-2018183411-A1 SMALL MOLECULE DCN1 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2018-10-04 WO claimed
EP-0213337-B1 4-CYANOPIPERIDINE DERIVATIVES, PREPARATION AND USE THEREOF Eisai Co., Ltd. (JP) 1991-05-15 EP claimed
WO-2025051241-A1 MACROCYCLIC COMPOUND AND ANTIBODY-DRUG CONJUGATE THEREOF 劲方医药科技(上海)股份有限公司 2025-03-13 WO disclosed
US-12012467-B2 Small molecule DCN1 inhibitors and therapeutic methods using the same REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2024-06-18 US disclosed
CN-114728917-B Oxamide derivative, preparation method and medical application thereof 深圳信立泰药业股份有限公司 2023-12-08 CN disclosed
CN-115819328-A Memantine urea derivative, preparation method thereof and application thereof in preparing medicine for treating soluble epoxide hydrolase mediated diseases 沈阳药科大学 2023-03-21 CN disclosed
CN-114728917-A Oxamide derivative, preparation method and medical application thereof 深圳信立泰药业股份有限公司 2022-07-08 CN disclosed
US-20210340121-A1 SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2021-11-04 US disclosed
WO-2021110076-A1 OXAMIDE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE 深圳信立泰药业股份有限公司 2021-06-10 WO disclosed
US-20110152235-A1 Aminopyrimidine Kinase Inhibitors Jasco Pharmaceuticals, LLC (US) 2011-06-23 US disclosed
WO-2002081466-A1 PRODRUGS OF 3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES SUGEN, INC. (US) 2002-10-17 WO disclosed
US-4721788-A 4-cyanopiperidine derivatives EISAI CO., LTD. (JP) 1988-01-26 US disclosed
US-4721788-A 4-cyanopiperidine derivatives EISAI CO., LTD. (JP) 1988-01-26 US disclosed
EP-0213337-A1 4-cyanopiperidine derivatives, preparation and use thereof Eisai Co., Ltd. (JP) 1987-03-11 EP disclosed
EP-0213337-A1 4-cyanopiperidine derivatives, preparation and use thereof Eisai Co., Ltd. (JP) 1987-03-11 EP disclosed
US-4243666-A HYPOTENSIVE AGENTS PFIZER INC. (US) 1981-01-06 US disclosed
US-4117140-A BRONCHODILATING PIPERIDINOETHYL BENZOPYRANOPYRIDINONES BROWN RICHARD E 1978-09-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210340121-A1 SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS GRIN2B, GRIN2A, GRIN3B GNAI3 602/4885GNAO1 200/4885GNAI1 384/4885
US-20200109167-A1 SMALL MOLECULE DCN1 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME DCUN1D2, CLN6, CAPNS1 GNAI3 2092/4885GNAO1 1681/4885GNAI1 1445/4885
US-12012467-B2 Small molecule DCN1 inhibitors and therapeutic methods using the same DCUN1D2, CLN6, CAPNS1 GNAI3 2092/4885GNAO1 1681/4885GNAI1 1445/4885
US-20110152235-A1 Aminopyrimidine Kinase Inhibitors PIM1, PIM2, PIM3 GNAI3 2677/4885GNAO1 3988/4885GNAI1 2124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.